Overview
ISO 18242:2016/Amd 1:2023 introduces an important amendment to the existing standard for centrifugal blood pumps used in cardiovascular implants and extracorporeal systems. This amendment specifically addresses the requirements for assessing centrifugal blood pumps under "worst-case conditions for testing." The document outlines the need for rigorous evaluations to enhance patient safety, promote product reliability, and establish consistent global benchmarks in the design and assessment of cardiovascular medical devices.
Key Topics
-
Worst-Case Condition Definition:
The amendment adds a new term, defining "worst-case condition" as the operating variables-within manufacturer’s specified ranges-representing the most challenging device operation for tests such as blood cell damage, bearing wear, backflow, and cavitation.
-
Testing Procedures:
Updated and expanded test procedures are detailed to ensure comprehensive assessment:
- Blood Cell Damage: Testing must include both non-pulsatile and pulsatile modes, with a focus on variables like pressure differential, afterload, flow rate, rotational speed, amplitude, and frequency.
- Pump Durability: Provisions require pumps to remain fully functional over manufacturer-specified durations, including new guidance for both non-pulsatile and pulsatile operation.
- Backflow in Pulsatile Mode: Tests must now demonstrate no backflow can occur under worst-case clinical conditions.
- Cavitation: Clear steps for verifying that cavitation does not occur during operation are introduced.
-
Sample Collection and Data Recording:
Tables dictate the schedule for measurement of plasma free haemoglobin, white blood cells, platelets, blood gas values, and other key markers throughout test durations.
-
Documentation of Frequency and Amplitude Limitations:
New mandatory inclusions for device frequency and amplitude limits in user documentation, aiding end-users in safer, more effective clinical application.
Applications
The revised guidelines within ISO 18242:2016/Amd 1:2023 are critical for healthcare technology manufacturers, regulatory bodies, and clinical evaluators involved with centrifugal blood pumps and extracorporeal support devices. Applications include:
- Product Development:
Manufacturers utilize these testing criteria to demonstrate centrifugal blood pump compliance and performance under stress, thereby ensuring robust, life-sustaining operation in real-world clinical environments.
- Regulatory Submissions:
Satisfying these global test benchmarks is often a prerequisite for device approval and market access in major jurisdictions.
- Quality Assurance:
Routine product verification and validation cycles leverage these tests for ongoing quality and patient safety improvement.
- Clinical Risk Management:
By identifying and addressing the actual "worst-case" clinical operating conditions, the standard plays a vital role in minimizing risk related to critical events such as blood cell damage or device failure.
Related Standards
ISO 18242:2016/Amd 1:2023 functions within a framework of international standards for cardiovascular devices, which include:
- ISO 18242:2016 – Cardiovascular implants and extracorporeal systems – Centrifugal blood pumps (base standard)
- ISO 5840 series – Heart valve prostheses
- ISO 10993 series – Biological evaluation of medical devices
- ISO 13485 – Quality management systems for medical devices
These standards collectively ensure the design, testing, and clinical performance of medical devices associated with cardiac care and extracorporeal circulation. Compliance with ISO 18242:2016/Amd 1:2023 supports global harmonization and enhances patient safety in cardiovascular therapy.
Keywords: ISO 18242:2016/Amd 1:2023, centrifugal blood pumps, cardiovascular implants, extracorporeal systems, worst-case testing, medical device standards, pump durability, blood cell damage, backflow, cavitation, clinical safety, regulatory compliance.